B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris,Bruce E. Johnson,Lynne D. Berry,David J. Kwiatkowski,A. John Iafrate,Ignacio I. Wistuba,Marileila Varella-Garcia,Wilbur A. Franklin,Samuel J. Aronson,Pei Fang Su,Yu Shyr,D. Ross Camidge,Lecia V. Sequist,Bonnie S. Glisson,Fadlo R. Khuri,Edward B. Garon,William Pao,Charles M. Rudin,Joan H. Schiller,Eric B. Haura,Mark A. Socinski,Keisuke Shirai,Heidi Chen,Giuseppe Giaccone,Giuseppe Giaccone,Marc Ladanyi,Kelly Kugler,John D. Minna,Paul A. Bunn +28 more
TL;DR: The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.
Journal ArticleDOI
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama,Esra A. Akbay,Yvonne Y. Li,Grit S. Herter-Sprie,Kevin A. Buczkowski,William G. Richards,Leena Gandhi,Amanda J. Redig,Scott J. Rodig,Hajime Asahina,Robert E. Jones,Meghana M. Kulkarni,Mari Kuraguchi,Sangeetha Palakurthi,Peter E. Fecci,Bruce E. Johnson,Pasi A. Jänne,Jeffrey A. Engelman,Sidharta P. Gangadharan,Daniel B. Costa,Gordon J. Freeman,Raphael Bueno,F. Stephen Hodi,Glenn Dranoff,Kwok-Kin Wong,Peter S. Hammerman,Peter S. Hammerman +26 more
TL;DR: Analysis of the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma suggests that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.
Journal ArticleDOI
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir,Barbara A. Weir,Michele S. Woo,Gad Getz,Sven Perner,Sven Perner,Li Ding,Rameen Beroukhim,Rameen Beroukhim,William M. Lin,William M. Lin,Michael A. Province,Aldi T. Kraja,Laura A. Johnson,Kinjal Shah,Kinjal Shah,Mitsuo Sato,Roman K. Thomas,Justine A. Barletta,Ingrid B. Borecki,Stephen R. Broderick,Andrew C. Chang,Derek Y. Chiang,Derek Y. Chiang,Lucian R. Chirieac,Jeonghee Cho,Yoshitaka Fujii,Adi F. Gazdar,Thomas J. Giordano,Heidi Greulich,Heidi Greulich,Megan Hanna,Megan Hanna,Bruce E. Johnson,Mark G. Kris,Alex E. Lash,Ling Lin,Neal I. Lindeman,Elaine R. Mardis,John Douglas Mcpherson,John D. Minna,Margaret Morgan,Mark Nadel,Mark Nadel,Mark B. Orringer,John R. Osborne,Brad Ozenberger,Alex H. Ramos,Alex H. Ramos,James T. Robinson,Jack A. Roth,Valerie W. Rusch,Hidefumi Sasaki,Frances A. Shepherd,Carrie Sougnez,Margaret R. Spitz,Ming-Sound Tsao,David Twomey,Roel G.W. Verhaak,George M. Weinstock,David A. Wheeler,Wendy Winckler,Wendy Winckler,Akihiko Yoshizawa,Soyoung Yu,Maureen F. Zakowski,Qunyuan Zhang,David G. Beer,Ignacio I. Wistuba,Mark A. Watson,Levi A. Garraway,Levi A. Garraway,Marc Ladanyi,William D. Travis,William Pao,Mark A. Rubin,Mark A. Rubin,Stacey Gabriel,Richard A. Gibbs,Harold E. Varmus,Richard K. Wilson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Matthew Meyerson,Matthew Meyerson +85 more
TL;DR: A large-scale project to characterize copy-number alterations in primary lung adenocarcinomas using dense single nucleotide polymorphism arrays identifies NKX2-1 (NK2 homeobox 1, also called TITF1), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate proto-oncogene involved in a significant fraction of lung carcinomas.
Journal ArticleDOI
LKB1 modulates lung cancer differentiation and metastasis
Hongbin Ji,Matthew R. Ramsey,D. Neil Hayes,Cheng Fan,Kate McNamara,Piotr Kozlowski,Chad Torrice,Michael C. Wu,Takeshi Shimamura,Samanthi A. Perera,Mei-Chih Liang,Dongpo Cai,George N. Naumov,Lei Bao,Cristina Contreras,Danan Li,Liang Chen,Janakiraman Krishnamurthy,Jussi Koivunen,Lucian R. Chirieac,Robert F. Padera,Roderick T. Bronson,Neal I. Lindeman,David C. Christiani,Xihong Lin,Geoffrey I. Shapiro,Pasi A. Jänne,Bruce E. Johnson,Matthew Meyerson,David J. Kwiatkowski,Diego H. Castrillon,Nabeel Bardeesy,Norman E. Sharpless,Kwok-Kin Wong +33 more
TL;DR: LKB1 is established as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis in lung cancer, and expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes as targets of LKB1 repression.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard,Egbert F. Smit,Harry J.M. Groen,Julien Mazieres,Benjamin Besse,Åslaug Helland,Vanessa Giannone,Anthony D'Amelio,Pingkuan Zhang,Bijoyesh Mookerjee,Bruce E. Johnson +10 more
TL;DR: Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC.